Quick Answer
AEON Biopharma, Inc. reported Total Assets of $5.56 million for fiscal year 2025.
AEON Biopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $5.56M | +77.0% |
| 2024 | $3.14M | -54.1% |
| 2023 | $6.84M | -36.5% |
| 2022 | $10.78M | -96.1% |
| 2021 | $276.95M | +341813.0% |
| 2020 | $81.0K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.73M | +118.1% | -25.1% |
| June 30, 2025 | $11.66M | +103.4% | -15.5% |
| March 31, 2025 | $13.80M | +355.1% | +339.2% |
| December 31, 2024 | $3.14M | -54.1% | -21.5% |
| September 30, 2024 | $4.00M | -77.3% | -30.2% |
| June 30, 2024 | $5.73M | -73.7% | +89.1% |
| March 31, 2024 | $3.03M | -86.0% | -55.7% |
| December 31, 2023 | $6.84M | -36.5% | -61.1% |
- AEON Biopharma, Inc. showed an increase of +77.0% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, AEON Biopharma, Inc.’s total assets has grown by 6764.2% (from $81.0 thousand to $5.56 million).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: